



(51) International Patent Classification:
C07D 213/38 (2006.01) **A61P 25/24** (2006.01)
A61K 31/4402 (2006.01)

(21) International Application Number:
PCT/SE2009/051493

(22) International Filing Date:
22 December 2009 (22.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/140,673 24 December 2008 (24.12.2008) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BALESTRA, Michael** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **BERNSTEIN, Peter** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **ERNST, Glen, E** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **FRIETZE, William** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **MC-CAULEY, John P** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **NUGIEL, David** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O.

Box 15437, Wilmington, DE 19850-5437 (US). **SHEN, Lihong** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION



(57) Abstract: The present invention relates to ethanamine compounds, namely 1- (3-f luorophenyl) -2-methyl-2- (pyridine-2-yl) propan-1-amine and 2-methyl-1-phenyl-2- (pyridine-2-yl) propan-1-amine, the enantiomers and salts thereof and their use for the treatment of depression.